HPR245 Baseline Characteristics of Patients Approved for Reimbursement of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland
Abstract
Authors
R Barrett A Smith C Gorry S Doran M Barry L Mccullagh